[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,074,368
  • Shares Outstanding, K 231,773
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 215 M
  • EBITDA $ 224 M
  • 60-Month Beta 0.73
  • Price/Sales 3.91
  • Price/Cash Flow 13.68
  • Price/Book 5.33

Options Overview Details

View History
  • Implied Volatility 63.10% (-1.47%)
  • Historical Volatility 34.91%
  • IV Percentile 46%
  • IV Rank 21.84%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 12) 0.74 (8.26%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 287
  • Volume Avg (30-Day) 444
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 72,369
  • Open Int (30-Day) 91,684
  • Expected Range 8.21 to 9.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.16
  • Number of Estimates 1
  • High Estimate $0.16
  • Low Estimate $0.16
  • Prior Year $0.15
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.46 +19.97%
on 06/03/26
9.04 -1.00%
on 06/25/26
+1.35 (+17.76%)
since 06/02/26
3-Month
7.45 +20.13%
on 06/02/26
11.42 -21.63%
on 04/24/26
-0.24 (-2.61%)
since 04/02/26
52-Week
7.21 +24.13%
on 03/26/26
20.46 -56.25%
on 12/12/25
-9.19 (-50.66%)
since 07/02/25

Most Recent Stories

More News
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS , July 3, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA...

ADMA : 8.95 (+3.95%)
ADMA INVESTOR REMINDER: ADMA Biologics, Inc. Investors Have Until August 10, 2026 To Seek Lead Plaintiff Role

If you have suffered a loss on your ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com...

ADMA : 8.95 (+3.95%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 2, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 8.95 (+3.95%)
ADMA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options

ADMA : 8.95 (+3.95%)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK , July 2, 2026 /PRNewswire/ -- 

ADMA : 8.95 (+3.95%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 1, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 8.95 (+3.95%)
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , July 1, 2026 /PRNewswire/ --  Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit...

ADMA : 8.95 (+3.95%)
ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline

ADMA Biologics allegedly certified internal controls as effective while concealing channel stuffing and an undisclosed related party distributor operating from company headquarters....

ADMA : 8.95 (+3.95%)
ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit

Did you buy ADMA securities between August 9, 2024 and March 25, 2026?

ADMA : 8.95 (+3.95%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 30, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 8.95 (+3.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 9.44
2nd Resistance Point 9.22
1st Resistance Point 9.09
Last Price 8.95
1st Support Level 8.74
2nd Support Level 8.52
3rd Support Level 8.39

See More

52-Week High 20.46
Fibonacci 61.8% 15.40
Fibonacci 50% 13.83
Fibonacci 38.2% 12.27
Last Price 8.95
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.